Cargando…
Exonuclease 1 genetic variant is associated with clinical outcomes of pemetrexed chemotherapy in lung adenocarcinoma
Pemetrexed is an anti-folate agent which is one of the most frequently used chemotherapy agents for non-squamous non-small cell lung cancer (NSCLC) patients. However, clinical response to pemetrexed chemotherapy and survival outcome of patients varies significantly. We evaluated whether the genetic...
Autores principales: | Hong, Mi Jeong, Park, Ji Eun, Lee, Shin Yup, Lee, Jang Hyuck, Choi, Jin Eun, Kang, Hyo-Gyoung, Do, Sook Kyung, Jeong, Ji Yun, Shin, Kyung Min, Lee, Won Ki, Seok, Yangki, Choi, Sun Ha, Lee, Yong Hoon, Seo, Hyewon, Yoo, Seung Soo, Lee, Jaehee, Cha, Seung Ick, Kim, Chang Ho, Park, Jae Yong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9809306/ https://www.ncbi.nlm.nih.gov/pubmed/36606188 http://dx.doi.org/10.7150/jca.78498 |
Ejemplares similares
-
Genetic Variants in Histone Modification Regions Predict Clinical Outcomes of Pemetrexed Chemotherapy in Lung Adenocarcinoma
por: Lee, Yong Hoon, et al.
Publicado: (2023) -
Intronic variant of EGFR is associated with GBAS expression and survival outcome of early‐stage non‐small cell lung cancer
por: Hong, Mi Jeong, et al.
Publicado: (2018) -
Genetic variants of NEUROD1 target genes are associated with clinical outcomes of small‐cell lung cancer patients
por: Lee, Sunwoong, et al.
Publicado: (2023) -
TSC2 genetic variant and prognosis in non‐small cell lung cancer after curative surgery
por: Lee, Yong Hoon, et al.
Publicado: (2018) -
Promoter-Specific Variants in NeuroD1 and H3K4me3 Coincident Regions and Clinical Outcomes of Small Cell Lung Cancer
por: Yoo, Seung Soo, et al.
Publicado: (2023)